Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia (Protocol A0081224)

Next Previous
Trial Profile

A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia (Protocol A0081224)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Postherpetic neuralgia
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 14 Oct 2014 Status changed from recruiting to completed according to ClinicalTrials.gov record.
  • 01 Oct 2014 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
  • 25 Feb 2014 Planned End Date changed from 1 Mar 2014 to 1 Sep 2014 according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top